Genital Herpes - Pipeline Review, Q1 2011
Global Markets Direct, February 2011, Pages: 34
Genital Herpes - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Genital Herpes - Pipeline Review, Q1 2011', provides an overview of the Genital Herpes therapeutic pipeline. This report provides information on the therapeutic development for Genital Herpes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Genital Herpes. 'Genital Herpes - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Genital Herpes.
- A review of the Genital Herpes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Genital Herpes pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Genital Herpes.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Genital Herpes pipeline depth and focus of Genital Herpes therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Genital Herpes Overview
Therapeutics Development
An Overview of Pipeline Products for Genital Herpes
Genital Herpes Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Genital Herpes Therapeutics Development
Antigenics, Inc.
Endo Pharmaceuticals Holdings Inc.
Starpharma Holdings Limited
Clavis Pharma ASA
Quigley Pharma, Inc.
AiCuris GmbH & Co. KG
BioVex, Inc.
NanoBio Corporation
Genocea Biosciences, Inc.
Genital Herpes - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
PRO 2000/5 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Genital Herpes - Featured News
1. Dec 08, 2010: AiCuris Completes Phase II Genital Herpes Trial With AIC316
2. Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
3. Aug 25, 2010: The Fourth Product Candidate Containing Antigenics’ QS-21 In Phase III Clinical Development - GSK Commences Phase III Clinical Trial With Shingles Vaccine Containing QS-21
4. Jul 27, 2010: Antigenics Announces Positive Phase I Trial Results Of AG-707 For Treatment Of Genital Herpes
5. Jul 27, 2010: Antigenics Presents Positive, Top Line Data from Phase I Herpes Clinical Trial
6. Mar 04, 2010: BioVex Commences Dosing In Phase I Study Of ImmunoVEX Live Attenuated Genital Herpes Vaccine
7. Mar 04, 2010: BioVex Commences Dosing In Phase I Study Of ImmunoVEX Live Attenuated Genital Herpes Vaccine
8. Feb 23, 2010: Genocea Biosciences Licenses Extensive Herpes Simplex Virus Patent Estate From The University Of Washington
9. Feb 23, 2010: Genocea Biosciences Licenses Extensive Herpes Simplex Virus Patent Estate From The University Of Washington
10. May 12, 2008: Starpharma Reports Positive VivaGel Clinical Study Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Genital Herpes, 2011
Products under Development for Genital Herpes – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Pre-Clinical Stage Development, 2011
Antigenics, Inc., 2011
Endo Pharmaceuticals Holdings Inc., 2011
Starpharma Holdings Limited, 2011
Clavis Pharma ASA, 2011
Quigley Pharma, Inc., 2011
AiCuris GmbH & Co. KG, 2011
BioVex, Inc., 2011
NanoBio Corporation, 2011
Genocea Biosciences, Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Genital Herpes, 2011
Products under Development for Genital Herpes – Comparative Analysis, 2011
Products under Development by Companies, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
